Recent

% | $
Quotes you view appear here for quick access.

Aethlon Medical, Inc. Message Board

  • robert.vince robert.vince Jan 17, 2013 10:05 AM Flag

    Aethlon Medical Announces the Appointment of Laszlo Radvanyi, Ph.D. to its Scientific Advisory Board

    SAN DIEGO, Jan. 17, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that Laszlo Radvanyi, Ph.D., an Associate Professor in the Department of Melanoma Medical Oncology Research at the University of Texas MD Anderson Cancer Center in Houston, has joined its Scientific Advisory Board.

    "I am excited to be a part of Aethlon's Scientific Advisory Board and its quest to develop clinical methods to remove exosomes from cancer patients. Exosomes are emerging as key long distance communicators of immune suppression in cancer throughout the body, especially through suppressive myeloid cells, and evidence is accumulating on the beneficial effects of exosome removal on anti-tumor immune responses," stated Dr. Radvanyi. "I am especially interested in working with Aethlon in developing research projects and clinical trials with the Hemopurifier as a synergistic therapy with other forms of immunotherapy in cancer patients to improve response rates and durability. Aethlon's technology removing exosomes in a non-invasive, simple, and safe fashion promises to catalyze a whole new approach to immunotherapy trials in cancer in the near future."

    Dr. Radvanyi received his Ph.D. in clinical biochemistry from the University of Toronto. His main research area is tumor immunology studying immune regulation in cancer and identifying new antigens as targets for anti-cancer T-cell therapy. After completing postdoctoral work in Toronto and at Harvard University in Boston at the Joslin Diabetes Center, Dr. Radvanyi joined the Immunology Group at Sanofi-Pasteur in Toronto in 2000 as a Senior Scientist where he helped lead an antigen discovery program that led to the discovery of a group of over-expressed breast cancer-specific genes that are candidates for antigen-specific vaccines against breast cancer. In 2005, Dr. Radvanyi joined the faculty of the University of Texas, MD Anderson Cancer Center, where he also holds the additional appointment as Associate Professor, Department of Breast Medical Oncology, Division of Cancer Medicine.

    "We are honored to have Dr. Radvanyi participate as a member of our Scientific Advisory Board and look forward to receiving his guidance as we advance our cancer treatment endeavors," stated Aethlon Medical Chairman and Chief Executive Officer, Jim Joyce.

    MD Anderson is one of the world's premier cancer centers. For the sixth year in a row, and the ninth time in the past 11 years, MD Anderson Cancer Center earned the No. 1 spot in U.S. News & World Report's annual rankings of the best hospitals for cancer care. Since the survey began in 1990, MD Anderson has been ranked every year as one of the top two hospitals in the nation for cancer care.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • And the M.D. Anderson link gets stronger! I still think we're going to see some kind of trials happening this year at Anderson. I don't know if AEMD has to get additional clearance from the FDA to do so, and if they have to wait until the HCV trials are completed (assuming they get the go-ahead to proceed), but I am seeing more and more evidence of an AEMD/Anderson collaboration. This could ultimately be really big news!
      Lee

    • beginning to think I might have been created a faux pas in selling 90% of mr shrs ;

      Sentiment: Strong Buy

 
AEMD
7.61-0.12(-1.55%)Sep 4 4:00 PMEDT